VOYA Investment Management
NGM

VOYA Investment Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

VOYA Investment Management’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-19,603
Closed -$50.8K – 2938
2023
Q2 		$50.8K Buy
19,603
+4,027
+26% +$14.4K ﹤0.01% 2899
2023
Q1 		$63.5K Hold
15,576
– – ﹤0.01% 2768
2022
Q4 		$78.2K Hold
15,576
– – ﹤0.01% 2798
2022
Q3 		$204K Buy
15,576
+1,078
+7% +$16.3K ﹤0.01% 2597
2022
Q2 		$186K Buy
14,498
+2,032
+16% +$28.1K ﹤0.01% 2425
2022
Q1 		$190K Hold
12,466
– – ﹤0.01% 2384
2021
Q4 		$221K Buy
12,466
+207
+2% +$3.97K ﹤0.01% 2455
2021
Q3 		$258K Hold
12,259
– – ﹤0.01% 2424
2021
Q2 		$242K Buy
12,259
+1,334
+12% +$31.2K ﹤0.01% 2491
2021
Q1 		$318K Buy
10,925
+467
+4% +$13.1K ﹤0.01% 2290
2020
Q4 		$317K Buy
+10,458
New +$229K ﹤0.01% 2167
2020
Q2 		– Sell
-12,524
Closed -$154K – 2649
2020
Q1 		$154K Buy
12,524
+882
+8% +$14.4K ﹤0.01% 2220
2019
Q4 		$215K Buy
+11,642
New +$170K ﹤0.01% 2349

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VOYA Investment Management's NGM Position: Q3 2023 in Review

VOYA Investment Management sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q3 2023, closing a stake of 19,603 shares — an estimated $50.8K sold.

VOYA Investment Management first reported a position in NGM in Q4 2019 and held it in 13 quarters. The position peaked at $318K in Q1 2021. 94 funds tracked by Wall St. Rank hold NGM as of Q3 2023.

  • VOYA Investment Management reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • VOYA Investment Management sold 19,603 NGM Biopharmaceuticals, Inc. Common Stock shares in Q3 2023, an estimated $50.8K.
  • VOYA Investment Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 13 quarters.
  • VOYA Investment Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $318K in Q1 2021.
  • 94 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2023.

Based on VOYA Investment Management's 13F filing for Q3 2023, filed 14 Nov 2023.